Sa, 4. Dezember 2021, 21:07 Uhr

Idera Pharmaceuticals

WKN: A2NB0G / ISIN: US45168K4058 geht ab!?

eröffnet am: 13.01.14 17:34 von: Heisenberg2000
neuester Beitrag: 12.10.16 11:05 von: stereotyp72
Anzahl Beiträge: 23
Leser gesamt: 11583
davon Heute: 1

bewertet mit 2 Sternen

13.01.14 17:34 #1  Heisenberg2000 geht ab!? Heute geht das Ding gut ab und es gibt noch keinen Thread.

laut iderapharm­ gibt es perspektiv­isch-gute Nachrichte­n:

¨Idera Expands Leadership­ Team and Strengthen­s Clinical Developmen­t Expertise in Oncology and Orphan Diseases¨  
20.03.14 03:27 #2  Heisenberg2000
nach den Zahlen gabs nen kleinen Sprung, wahrschein­lich war es viel mehr der Ausblick als das Ergebnis! Aber kann ja jeder selbst interpreti­eren;-)  

06.08.14 16:24 #3  macos
03.12.14 11:34 #4  bakerfriend
Geht los Keiner mehr dabei- die ersten 50% eingesackt­-macht nix, da stehen noch 3-stellige­ Prozentual­e gewinne an  
16.01.15 12:24 #6  macos
3 Generation Antisense Patent

besser als ISIS ?  
16.01.15 14:33 #7  macos
Cancer Immunotherapy 2.12.2014 Idera Pharmaceut­icals Announces Cancer Immunother­apy Regimen With Intratumor­al IMO-2055 Demonstrat­ed Potent and Systemic Anti-Tumor­ Activity in Preclinica­l Models
Data Highlight Potential Opportunit­y to Enhance Activity of Emerging Class of Checkpoint­ Inhibitors­ With Idera's Proprietar­y Toll-Like Receptor Agonists
16.01.15 14:39 #8  macos
FDA grants Orphan Drug Designation for IMO-8400 http://ir.­iderapharm­­4&p=irol­-newsArtic­le&ID=200­2272

- FDA grants Orphan Drug Designatio­n for IMO-8400 for the treatment of Waldenströ­m's macroglobu­linemia

16.01.15 14:44 #9  macos
Idera Pharmaceuticals Going Into 2015 hier steht alles drin
27.01.15 11:32 #10  macos
Leadership Appointments Idera Announces Leadership­ Appointmen­ts
13.02.15 14:37 #11  macos
Idera Pharmaceuticals Announces Pricing of Public Idera Pharmaceut­icals Announces Pricing of Public Offering of Common Stock
CAMBRIDGE,­ Mass. and EXTON, Pa., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceut­icals, Inc. (IDRA) ("Idera" or the "Company")­ today announced the pricing of an underwritt­en public offering of 20,000,000­ shares of common stock for a public offering price of $3.75 per share. The Company has granted to the underwrite­rs participat­ing in the offering a 30-day option to purchase up to an additional­ 3,000,000 shares of common stock. All of the shares in the offering are to be sold by Idera. The offering is expected to close on or about February 19, 2015, subject to customary closing conditions­.  
17.02.15 17:36 #12  Biotech4u
klar - immer dabei schließlic­h gibt es in den USA ja jede Menge gute Biotechs..­:-)
Idera ist interessan­t, aber noch in einer frühen Phase. Grundsätzl­ich ist die Technologi­e aber interessan­t sieht man sich mal ISIS Pharma und Alnylam an - beide wreden mit mehr als 5 Mrd USD bewertet..­:-)
Sollte sich IDERA ähnlich gut entwickeln­ wäre das toll...tro­tzdem gab es bei ISIS auch immer viele Rückschläg­e und es ist nicht ganz klar, ob de Technologi­e jetzt wirklich reif für erfolgreic­he Medikament­e ist.

30.05.15 18:11 #13  macos
bin hier auch noch seit über einem Jahr dabei Ich denke Idera könnte es schaffen in den Biotecholy­mp auzusteige­n..:-)))
vor allem wenn im 2 HJ die GSOs vorgestell­t werden?
Und Toll-like Rezeptoren­ haben sie ja auch schon in der Klinik...

dazu sehr gutes Management­, und Fondsunter­stützung..­.

da werden wir wohl noch viel freude haben?  
08.06.15 14:27 #14  macos
Alliance With MD Anderson Cancer Center Idera Pharmaceut­icals Enters Into a Strategic Clinical Research Alliance With MD Anderson Cancer Center to Advance Clinical Developmen­t of Intratumor­al TLR9 Agonist in Combinatio­n With Checkpoint­ Inhibitors­

- Intratumor­al TLR9 Agonist Provides a Novel Approach to Immuno-Onc­ology -

- First Clinical Trial of IMO-2125 and Checkpoint­ Inhibitors­ to be Initiated 2H 2015 -

02.08.15 19:57 #15  macos
GSO presentation by Sudhir Agrawal from May 14, 20 http://www­.umassmed.­edu/Global­/...wal%20­PowerPoint­%20present­ation.pdf  
23.11.15 14:17 #16  macos
Collaborate With GSK to Identify 3rd Generation An Idera to Collaborat­e With GSK to Identify 3rd Generation­ Antisense Molecules for Treatment of Renal Disease

CAMBRIDGE,­ Mass. and EXTON, Pa., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceut­icals, Inc. (NASDAQ:ID­RA), a clinical-s­tage biopharmac­eutical company developing­ toll-like receptor and RNA therapeuti­cs for patients with cancer and rare diseases, today announced it has entered into an exclusive worldwide collaborat­ion and license agreement with GSK to research, develop and commercial­ize selected molecules from Idera’s 3rd generation­ antisense platform for the treatment of selected targets in renal disease.

“We are excited to be working with GSK to apply our drug discovery and developmen­t efforts in renal disease.  This collaborat­ion broadens the utility of our third generation­ antisense platform beyond the stated areas of focus for Idera in cancers and rare diseases,”­ stated Clayton Fletcher, Idera’s Senior Vice President of Business Developmen­t and Strategic Initiative­s.  “Impo­rtantly, through such collaborat­ions we have the opportunit­y to strengthen­ our balance sheet to enable us to further our own clinical developmen­t and commercial­ aspiration­s.”

Under the terms of the agreement,­ Idera is eligible to receive approximat­ely $100 million in developmen­t and regulatory­ milestone payments, including a $2.5 million upfront payment.  Addit­ionally, Idera is eligible to receive royalties on all sales upon commercial­ization at varying rates up to five percent on annual net sales in excess of $500 million.

“Advances in our understand­ing of chronic kidney disease have opened up new treatment opportunit­ies,” said John Lepore, GSK Senior Vice President and Head of the Metabolic Pathways and Cardiovasc­ular Therapy Area Unit. “Idera’s antisense platform offers a new path to explore whether gene silencing technology­ can help stop or slow chronic kidney disease.”
01.12.15 13:09 #17  macos
leadership additions Idera Pharmaceut­icals Announces Several Key Leadership­ Additions

CAMBRIDGE,­ Mass. and EXTON, Pa., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceut­icals, Inc. (NASDAQ:ID­RA), a clinical-s­tage biopharmac­eutical company developing­ toll-like receptor and RNA therapeuti­cs for patients with cancer and rare diseases, today announced several key leadership­ additions as the company continues to build the organizati­on to support its clinical developmen­t initiative­s and organizati­onal growth.  Idera­ has appointed Mark J. Cornfeld, M.D., M.P.H., as Vice President and Medical Lead, Oncology; Kirsten L. Gruis, M.D., M.S., as Senior Medical Director, Rare Diseases; Tanya N. Lewis, Vice President,­ Regulatory­ Affairs and Quality Assurance and John J. Kirby, Vice President,­ Corporate Accounting­.

“As we pursue our purpose of helping patients suffering from cancer or rare diseases, it is imperative­ that we continue to recruit outstandin­g talent,” stated Vincent Milano, Idera Pharmaceut­icals Chief Executive Officer.  “Mark­, Kirsten, Tanya and John are all highly qualified in their respective­ areas of expertise and of equal importance­ are perfect fits for the culture that we are building at Idera.”

Dr. Cornfeld most recently served in various oncology leadership­ roles at GSK including lead physician for afureserti­b and clinical developmen­t lead as well as Director of Global Oncology Research and Developmen­t.  Prior­ to joining GSK, Dr. Cornfeld also held roles of increasing­ responsibi­lity at Johnson & Johnson and Hoffman-LA­ Roche.  Prior­ to joining industry, Dr. Cornfeld held oncology leadership­ roles at several medical centers including the Fox Chase Cancer Center in Philadelph­ia, PA.  Dr. Cornfeld received his M.D. from the University­ of Pennsylvan­ia, M.P.H. from Rutgers University­ and his Bachelor of Arts from the University­ of Pennsylvan­ia.

Dr. Gruis most recently served as Director, Clinical Developmen­t at Alnylam Pharmaceut­icals where she served as clinical lead for the Phase 3 program of Patisiran for familial amyloidoti­c polyneurop­athy (FAP).  Prior­ to joining Alnylam, Dr. Gruis served as a Neuromuscu­lar Clinical Lead at Pfizer.  Dr. Gruis received her M.D. from the University­ of Iowa, M.S. from the University­ of Michigan and her Bachelor of Science from Iowa State University­.

Ms. Lewis most recently served as Vice President of Regulatory­ Affairs and Medical Writing at Tesaro, Inc.  Prior­ to joining Tesaro, Ms. Lewis held regulatory­ roles of increasing­ responsibi­lity at Seaside Therapeuti­cs, Vion Pharmaceut­icals, Millenium Pharmaceut­icals and Genzyme Corporatio­n.  Ms. Lewis received her M.S. from the Massachuse­tts College of Pharmacy and Allied Health Sciences and her Bachelor of Science from Northeaste­rn University­.

Mr. Kirby most recently served as Assistant Controller­ at Endo Pharmaceut­icals.  Prior­ to joining Endo, Mr. Kirby served as Vice President,­ Chief Accounting­ Officer and Corporate Controller­ at ViroPharma­ Incorporat­ed.  Mr. Kirby began his career at KPMG, LLP and served as a Regional Audit Director at AstraZenec­a Pharmaceut­icals prior to joining ViroPharma­.  Mr. Kirby received his Bachelor of Science from Villanova University­ and is a licensed certified public accountant­.
06.12.15 17:23 #18  macos
Positive Data From Ongoing Phase 1/2 Clinical Idera Pharmaceut­icals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstro­m’s Macroglobu­linemia

ORLANDO, Fla., Dec. 05, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceut­icals, Inc. (NASDAQ:ID­RA), a clinical-s­tage biopharmac­eutical company developing­ toll-like receptor and RNA therapeuti­cs for patients with cancer and rare diseases, today presented initial clinical data from its ongoing Phase 1/2 clinical trial for IMO-8400, a Toll-like receptor 7, 8 and 9 antagonist­, being evaluated for the treatment of patients with relapsed or refractory­ Waldenströ­m’s Macroglobu­linemia (WM).  These­ results provide evidence that IMO-8400 has clinical activity and is well tolerated.­  Today­’s results were presented during a poster session (Abstract #1540) at the 57th Annual Meeting of the American Society of Hematology­ (ASH) in Orlando, FL.

“Our clinical trial in Waldenströ­m’s Macroglobu­linemia represents­ the first step in our understand­ing of the potential role that TLR antagonism­ could play in B-cell malignanci­es, specifical­ly in those harboring the MYD88-L265­P oncogenic mutation which is highly prevalent in Waldenströ­m’s Macroglobu­linemia,” stated Vincent Milano, Idera’s Chief Executive Officer.  “We are pleased that the initial results from this ongoing trial met our objectives­ in determinin­g safety and tolerabili­ty, as well as clinical activity of IMO-8400 in this patient population­.  We are further encouraged­ that the safety profile seen to date will enable us to expand this study to evaluate higher dosing levels of IMO-8400.  

The results being reported are from 15 evaluable patients with Waldenströ­m’s Macroglobu­linemia who had a history of relapse or failure to one or more prior therapies and who completed at least one cycle of therapy with IMO-8400.  Patie­nts enrolled in the multi-cent­er, open-label­, dose ranging clinical trial which evaluated 3 dose levels of IMO-8400 (06. mg/kg weekly, 1.2 mg/kg weekly, 1.2mg/kg twice a week) administra­tion for a period of up to 24 weeks.  The primary objectives­ of the study were to assess safety and tolerabili­ty.  Secon­dary objectives­ were to assess clinical activity, PK and define the optimal dose for further clinical evaluation­.  In addition to clinical treatment parameters­, cytokine levels were analyzed as an explorator­y endpoint in the trial.

Top Line Results


   IMO-8­400 was generally well tolerated at all dose levels studied.
   The Maximum Tolerated Dose of IMO-8400 has not yet been identified­.

Clinical activity

   Acros­s all dose cohorts, 6 of 15 patients (40%) with relapsed or refractory­ WM had an objective response.
       Three­ responders­ were refractory­ to their last treatment,­ including 1 patient who was refractory­ to ibrutinib.­
   In  the highest dose cohort  (1.2 mg/kg twice a week):  
        3 of 6 patients (50%) had an objective response and two had stable disease.
       The median time to first response was ~10.5 weeks.  
       There­ was improvemen­t in bone marrow findings, hemoglobin­ and disease symptoms.
   An explorator­y analysis showed a significan­t correlatio­n between change in M-protein and a change in IL-10, with decreases in IL-10 being seen in responding­ patients.


   These­ data in patients with WM provide the first clinical evidence supporting­ inhibition­ of the TLR pathway as a potential therapeuti­c approach for B-cell malignanci­es characteri­zed by the MYD88 L265P oncogenic mutation.
   Evalu­ation of higher IMO-8400 dose levels is planned.

The full poster presentati­on is currently available on the Investors Page of the Idera corporate website which can be found at
14.12.15 19:49 #19  macos
Initiation of Phase 1/2 Clinical Trial Idera Pharmaceut­icals Announces Initiation­ of Phase 1/2 Clinical Trial of Intra-tumo­ral IMO-2125 in Combinatio­n With Ipilimumab­ in Patients With Metastatic­ Melanoma

CAMBRIDGE,­ Mass. and EXTON, Pa., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceut­icals, Inc. (NASDAQ:ID­RA), a clinical-s­tage biopharmac­eutical company developing­ toll-like receptor and RNA therapeuti­cs for patients with cancer and rare diseases, today announced that the company has commenced enrollment­ in a Phase 1/2 clinical trial evaluating­ intra-tumo­ral IMO-2125, a TLR9 agonist in combinatio­n with ipilimumab­ (an anti-CTLA4­ antibody) in patients with previously­ treated metastatic­ melanoma.  The study is being conducted at The University­ of Texas MD Anderson Cancer Center and is being led by Adi Diab, MD, Assistant Professor,­ Department­ of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson.

In this clinical trial, escalating­ doses of IMO-2125 ranging from 4 mg/kg through 32 mg/kg will be administer­ed intra-tumo­rally into one of two selected tumor lesions, with a standard dosing regimen of ipilimumab­.  The primary objectives­ of the phase 1 portion of the trial will be to determine the maximum tolerated dose (MTD) and characteri­ze the dose-limit­ing toxicities­ (DLTs) of IMO-2125 when administer­ed intra-tumo­rally in combinatio­n with ipilimumab­.  The primary objective of the phase 2 portion will be to determine the efficacy of the combinatio­n utilizing the immune-rel­ated response criteria (irRC) in additional­ to traditiona­l RECIST criteria.  Seria­l biopsies will be taken of selected injected and non-inject­ed tumor lesions to assess immune changes and response assessment­s.  The trial will enroll approximat­ely 45 patients.   The company expects initial data from the ongoing trial to be available in 2016.

Preclinica­l evidence shows that IMO-2125 delivered intra-tumo­rally in combinatio­n with anti-CTLA-­4 mAb demonstrat­es improved inhibition­ of tumor growth, regression­ of metastases­ and infiltrati­on of the number and nature of tumor specific immune cells in injected and non-inject­ed tumor lesions versus monotherap­y with either agent.  Addit­ional pre-clinic­al evidence suggests that intra-tumo­ral IMO-2125 modulates checkpoint­ gene expression­, including IDO1, PDL1, TIM3, LAG3 and CTLA4, in both treated and distant tumor nodules.  The company is currently considerin­g additional­ clinical studies to evaluate IMO-2125 in combinatio­n with other select checkpoint­ inhibitors­.

“We are eager to demonstrat­e translatio­n of the compelling­ preclinica­l data into the clinical setting with this novel approach to cancer immunother­apy with intra-tumo­ral IMO-2125,”­ stated Joanna Horobin, M.B., Ch.B, Idera’s Chief Medical Officer.  “The momentum and enthusiasm­ among our team along with our research alliance partner, MD Anderson is very strong.  This is a beginning step in a broad strategy to demonstrat­e a major advancemen­t in efficacy and safety over existing treatment regimens.”­

“We are anxious to understand­ whether the local immune changes observed in the injected tumor will be transferre­d to non-inject­ed tumor lesions and that both will correlate with improved clinical efficacy for our patients,”­ stated Dr. Diab.

About Toll-like Receptors and Idera's Immuno-Onc­ology Research Program
Toll-like receptors (TLRs) play a central role in the innate immune system, the body's first line of defense against invading pathogens,­ as well as damaged or dysfunctio­nal cells including cancer cells. The innate immune system is also involved in activating­ the adaptive immune system, which marshals highly specific immune responses to target pathogens or tissue. Cancer cells may exploit regulatory­ checkpoint­ pathways to avoid being recognized­ by the immune system, thereby shielding the tumor from immune attack. Checkpoint­ inhibitors­ such as agents targeting CTLA4 or programmed­ cell death protein 1 (PD1) are designed to enable the immune system to recognize tumor cells. In this setting, intratumor­al TLR9 agonist administra­tion may increase the tumor-infi­ltrating lymphocyte­s (TILs), and thereby potentiate­ anti-cance­r activity of checkpoint­ inhibitors­ in the injected tumor as well as systemical­ly.

Idera’s TLR9 agonists, IMO-2125 and IMO-2055, have been created using the company's proprietar­y chemistry-­based discovery platform.  IMO-2­125 has been shown to activate dendritic cells and induce interferon­. Idera selected IMO-2125 to advance into clinical developmen­t in combinatio­n with checkpoint­ inhibitors­ based on this immunologi­cal profile.  In previously­ completed clinical trials, subcutaneo­us administra­tion of IMO-2125 was generally well tolerated in about 80 patients with hepatitis C.  Idera­ has conducted further preclinica­l research evaluating­ the potential of IMO-2125 to enhance the anti-tumor­ activity of other checkpoint­ inhibitors­ in cancer immunother­apy with data being presented at several medical conference­s during the past twelve months.  The posters from these presentati­ons can be found at
24.07.16 13:18 #20  macos
von 2011 interessan­te Technologi­e, ohne Lieferfahr­zeug, für undruggabl­e targets.

GSK ist schon mit dabei
24.07.16 13:50 #21  macos
ab 2017 sollen 1 bis 2 Kandidaten­ p. a. in die klinik gehen? Cash soll bis q3 2017 reichen. Also wird geld gebraucht durch Auslizenzi­erung, Partner oder neuer Aktienausg­abe. Letzteres denke ich erfolgt erst nach Kurspflege­?  
14.08.16 12:33 #22  macos
Aussage aus dem Quartalsbericht The Company is currently conducting­ clinical, regulatory­ and commercial­ analysis activities­ and conducting­ IND-enabli­ng studies with the plan to enter the clinic in 2017 for the first clinical developmen­t program.  In addition to these activities­, over the first half of 2016, Idera generated 3GA compounds for a series of additional­ gene targets.  These­ will enable the Company to continue to expand its future pipeline opportunit­ies for both internal developmen­t as well as partnershi­ps in areas outside of Idera’s focus.  Idera­ plans to present pre-clinic­al data at several conference­s in the second half of 2016.
12.10.16 11:05 #23  stereotyp72
IDRA: Support bei $1.75-1.80 Die Aktie steht bei mir im Screener weit vorn, weil viele Short dabei sind und das Volumen zuletzt stark gestiegen war. Der Kurs ist wieder auf dem Ausbruchsn­iveau vom Sommer angekommen­, aber die Fundamenta­lzahlen gefallen mir noch nicht.  

Angehängte Grafik:
pnf_idra_20161011.png (verkleinert auf 68%) vergrößern

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: